Evaluation of Baseline Factors on Progression in a Large Phase-2 Clinical Trial for Geographic Atrophy (FILLY Study)

被引：0

作者：

Steinle, Nathan ^{[1
]}

Hamdani, Mohamed ^{[1
]}

机构：

[1] Calif Retina Consultants, Arroyo Grande, CA USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2019年 / 60卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

973

引用

页数：2

共 50 条

[41] Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration A Post Hoc Analysis of the FILLY Randomized Clinical Trial
Nittala, Muneeswar Gupta
Metlapally, Ravi
Ip, Michael
Chakravarthy, Usha
Holz, Frank G.
Staurenghi, Giovanni
Waheed, Nadia
Velaga, Swetha Bindu
Lindenberg, Sophiana
Karamat, Ayesha
Koester, John
Ribeiro, Ramiro
Sadda, SriniVas
JAMA OPHTHALMOLOGY, 2022, 140 (03) : 243 - 249
[42] PHASE-2 CLINICAL-TRIAL OF PEPTICHEMIO - CLINICAL SCREENING COOPERATIVE GROUP OF EUROPEAN ORGANIZATION ON RESEARCH ON TREATMENT OF CANCER (EORTC)
不详
BIOMEDICINE EXPRESS, 1977, 27 (08): : 290 - 294
[43] Phase 2b Study of Brimonidine DDS: Potential Novel Treatment for Geographic Atrophy
Freeman, William R.
Bandello, Francesco
Souied, Eric H.
Guymer, Robyn H.
Garg, Sunir
Chen, Fred Kuanfu
Rich, Ryan M.
Holz, Frank G.
Li, Yan
Kerr, Kevin
Lopez, Francisco J.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[44] Data-Driven Prior Distributions for A Bayesian Phase-2 COPD Dose-Finding Clinical Trial
Novick, Steven
Ho, Shuyen
Best, Nicky
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2018, 10 (03): : 166 - 175
[45] Baseline characteristics, natural history, and risk factors to progression in eyes with stage 2 macular holes - Results from a prospective randomized clinical trial
Kim, JW
Freeman, WR
ElHaig, W
Maguire, AM
Arevalo, JF
Azen, SP
Abrams, G
Dosick, RW
Feldman, ST
Fine, SL
Bailey, I
Aaberg, T
Berger, B
Blankenship, GW
Brucker, AJ
deBustros, S
Gilbert, H
Han, DP
Kokame, G
McCuen, B
Frambach, DA
Olk, J
Sipperley, JO
Teeters, VW
Wood, W
Yoshida, A
OPHTHALMOLOGY, 1995, 102 (12) : 1818 - 1828
[46] The Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients with Geographic Atrophy (OMEGA) Study: Design and Baseline Characteristics (OMEGA report 1)
Ansari, Georg
Scharer, Nils
Zuche, Hanna Camenzind
Gabrani, Chrysoula
Anders, Philipp
Pfau, Kristina
Valmaggia, Philippe
Giani, Andrea
Esmaeelpour, Marieh
Yamaguchi, Taffeta Chingning
Prunte, Christian F.
Maloca, Peter M.
Schmetterer, Leopold
Scholl, Hendrik P. N.
Pfau, Maximilian
OPHTHALMIC RESEARCH, 2023, 66 (01) : 1392 - 1401
[47] SAMELISANT (SUVN-G3031), BASELINE CHARACTERISTICS FROM A PHASE-2 STUDY EVALUATING EFFICACY AND SAFETY IN PATIENTS WITH NARCOLEPSY
Nirogi, Ramakrishna
Ravula, Jyothsna
Jayarajan, Pradeep
Goyal, Vinod Kumar
Jetta, Satish
Shinde, Anil
Benade, Vijay
Jasti, Venkat
SLEEP, 2022, 45 : A274 - A274
[48] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
Tiacci, Enrico
De Carolis, Luca
Simonetti, Edoardo
Merluzzi, Mara
Bennati, Antonio
Perriello, Vincenzo Maria
Pucciarini, Alessandra
Santi, Alessia
Venanzi, Alessandra
Pettirossi, Valentina
Schiavoni, Gianluca
Tasselli, Luisa
Ascani, Stefano
Volpetti, Stefano
Falini, Brunangelo
LEUKEMIA, 2021, 35 (11) : 3314 - 3318
[49] CANCER-TREATMENT TODAY AND ITS IMPACT ON DRUG DEVELOPMENT, WITH SPECIAL EMPHASIS ON PHASE-2 CLINICAL-TRIAL
CARTER, SK
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1976, 57 (02): : 235 - 244
[50] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
Enrico Tiacci
Luca De Carolis
Edoardo Simonetti
Mara Merluzzi
Antonio Bennati
Vincenzo Maria Perriello
Alessandra Pucciarini
Alessia Santi
Alessandra Venanzi
Valentina Pettirossi
Gianluca Schiavoni
Luisa Tasselli
Stefano Ascani
Stefano Volpetti
Brunangelo Falini
Leukemia, 2021, 35 : 3314 - 3318

← 1 2 3 4 5 →